LakeShore Biopharma Co Receivables

The latest receivables for LSB is $500M as of March 2025. That compares with $440M in the prior-year period — up 13.0% year over year. Investors often review this figure alongside LakeShore Biopharma Co's historical trend and sector peers before judging valuation or financial health.

Over the past year, LSB's receivables moved from $440M to $500M — a 13.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in LakeShore Biopharma Co's operating scale or balance-sheet position.

A receivables figure of $500M for LSB is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting LSB's receivables ($500M), review year-over-year change from $440M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.